Robert McRae
Keine laufenden Positionen mehr
Vermögen: 1 735 $ am 31.03.2024
Profil
Robert McRae worked as Vice President-Operations at Viracta Subsidiary, Inc. from 2018 to 2020.
He also held the position of Vice President-Operations & Strategic Alliances at Viracta Therapeutics, Inc. Additionally, he served as Chief Operating Officer at Palisade Bio, Inc. in 2023.
Mr. McRae obtained his undergraduate degree from Wright State University (Ohio).
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
PALISADE BIO, INC.
0,03% | 15.03.2024 | 4 348 ( 0,03% ) | 1 735 $ | 31.03.2024 |
Ehemalige bekannte Positionen von Robert McRae
Unternehmen | Position | Ende |
---|---|---|
PALISADE BIO, INC. | Chief Operating Officer | 01.05.2023 |
VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Operating Officer | - |
Ausbildung von Robert McRae
Wright State University (Ohio) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
VIRACTA THERAPEUTICS, INC. | Health Technology |
PALISADE BIO, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |